Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC.

Journal Article (Clinical Trial, Phase III;Journal Article)

BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms (DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-based engineering tool. RESULTS: Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than 10 % for most criteria; however, a deviation unacceptable rate of more than 20 % was computed for the planning target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters in which PSPT plans resulted in lower values than IMRT plans were: lung V5Gy (%) (34.4 in PSPT and 47.2 in IMRT); maximum spinal cord dose (31.7 Gy in PSPT and 43.5 Gy in IMRT); heart V5Gy (%) (19 in PSPT and 47 in IMRT); heart V30Gy (%) (11 in PSPT and 19 in IMRT); heart V45Gy (%) (7.8 in PSPT and 12.1 in IMRT); heart V50% (Gy) (7.1 in PSPT and 9.8 in IMRT) and mean heart dose (7.7 Gy in PSPT and 14.9 Gy in IMRT). CONCLUSIONS: The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable.

Full Text

Duke Authors

Cited Authors

  • Giaddui, T; Chen, W; Yu, J; Lin, L; Simone, CB; Yuan, L; Gong, YUT; Wu, QJ; Mohan, R; Zhang, X; Bluett, JB; Gillin, M; Moore, K; O'Meara, E; Presley, J; Bradley, JD; Liao, Z; Galvin, J; Xiao, Y

Published Date

  • May 4, 2016

Published In

Volume / Issue

  • 11 /

Start / End Page

  • 66 -

PubMed ID

  • 27142674

Pubmed Central ID

  • PMC4855766

Electronic International Standard Serial Number (EISSN)

  • 1748-717X

Digital Object Identifier (DOI)

  • 10.1186/s13014-016-0640-8


  • eng

Conference Location

  • England